Dare Bioscience vs Lipocine
DARE and LPCN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DARE and LPCN compare
Lipocine is the larger company, worth 1.4 times as much as Dare Bioscience ($14.1M against $10.1M).
Lipocine keeps more of each dollar of sales as profit, with a net margin of −249% compared with −804% at Dare Bioscience.
Lipocine scores higher on the StockData Score (11 against 5 for Dare Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DARE | LPCN |
|---|---|---|
| Size and price | ||
| Market cap | $10.1M | $14.1M |
| Share price | $0.657 | $1.71 |
| Change, 1 year | −66.8% | −41.4% |
| Change, 5 years | −96.7% | −91.4% |
| Beta (5Y) | 1.40 | 0.66 |
| Employees | 24 | 14 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.4× | 3.8× (better) |
| P/B | – | 0.7× |
| FCF yield | −117% | – |
| Fair value | – | $3.29 |
| Margin of safety | – | 48.0% |
| Growth | ||
| Revenue growth (TTM) | – | −13.4% |
| Profitability | ||
| Operating margin | −813% | −269% (better) |
| Net margin | −804% | −249% (better) |
| FCF margin | −861% | – |
| Return on equity | – | −52.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.99 | 11.36 (better) |
| Altman Z-score | −13.51 | −9.08 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −114% |
| Shareholder yield | 0.00% (better) | −114% |
| Ownership | ||
| Held by institutions | 8.5% | 36.2% |
| Held by insiders | 9.4% | 8.4% |
| Insider net buying, 12 months | – | $517K |
| Short interest, % of float | 7.1% | 4.3% |
Go deeper
- DARE stock overview
- DARE income statement
- DARE valuation and score
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.